Business
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset
About this update from Ac Immune Sa
[{"type":"text","content":"Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints Initial data will be presented at the Alzheimer's Association International Conference (AAIC) on August 2, 2022 LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced results from the Alzheimer’s Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial. The study evaluated the potential of crenezumab, an investigational medicine, to slow or prevent Alzheimer’s disease in cognitively unimpaired people who carry a specific genetic mutation which causes early-onset Alzheimer’s disease. Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints, though none were statistically significant. The co-primary endpoints assessed the rate of change in cognitive abilities or episodic memory function, measured by the API ADAD composite cognitive total score and the Free and Cued Selective Reminding Test (FCSRT) Cueing Index, respectively. Crenezumab was generally well tolerated during the study and no new safety issues were identified. Further analyses of data are ongoing. Initial data will be presented at the Alzheimer's Association International Conference (AAIC) on August 2, 2022. Dr. Andrea Pfeifer, CEO of AC Immune commented: “While we are disappointed that the primary endpoints were not met, crenezumab’s safety profile and the favorable numerical differences observed across primary, secondary and exploratory endpoints, warrant further analyses of the data. “We are grateful to all those involved in this landmark study, which will undoubtedly increase the scientific community’s understanding of pre-symptomatic Alzheimer’s disease and prevention studies conducted in this population. We would like to especially recognize the trial participants and their families, whose courage continues to inspire us. We also thank our colleagues and partners at the Banner Alzheimer’s Institute (BA...